DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9.266,901 B2 Pietras Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9.266,901 B2 Pietras Et Al USOO9266901 B2 (12) United States Patent (10) Patent No.: US 9.266,901 B2 Pietras et al. (45) Date of Patent: Feb. 23, 2016 (54) COMPOSITIONS AND METHODS FOR (58) Field of Classification Search TREATING CANCER CPC ..................................................... CO7D 493/04 USPC .......................................................... 549/299 (71) Applicant: The Regents of the University of See application file for complete search history. California, Oakland, CA (US) (56) References Cited (72) Inventors: Richard J. Pietras. Sherman Oaks, CA (US); Michael E. Jung, Los Angeles, U.S. PATENT DOCUMENTS CA (US); Diana C. Marquez-Garban, 6,890,946 B2 5/2005 Nakshatri et al. Los Angeles, CA (US); Gang Deng, Los 7.312,242 B2 12/2007 Crooks et al. Angeles, CA (US) 7,678,904 B2 * 3/2010 Crooks ................ CO7D 307.77 544,153 (73) Assignee: The Regents of The University of 8,124,652 B2 2/2012 Crooks et al. 2002fOO58077 A1 5, 2002 Shen et al. Califronia, Oakland, CA (US) 2004/0229936 A1 11/2004 Hsieh et al. (*) Notice: Subject to any disclaimer, the term of this 2010, OOO997O A1 1/2010 Johansen et al. patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. FOREIGN PATENT DOCUMENTS WO WO-2005/007103 A2 1, 2005 (21) Appl. No.: 14/505,288 OTHER PUBLICATIONS (22) Filed: Oct. 2, 2014 Nasim Bioorganic & Medicinal Chemistry Letters 18 (2008) 3870 (65) Prior Publication Data 3873.* Neukirch, Bioorganic & Medicinal Chemistry (2003), 11(7), 1503 US 2015/OO31725A1 Jan. 29, 2015 151O.* Hwang et al., “Synthesis and anti-viral activity of a series of Related U.S. Application Data sesquiterpene lactones and analogues in the Subgenomic HCV replicon system.” Bioorg Med. Chemistry, 13:83-91 (2006). (63) Continuation of application No. PCT/US2013/ Neelakantan et al., "Aminoparthenolides as novel anti-leukemic 035.010, filed on Apr. 2, 2013. agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1).” (60) Provisional application No. 61/619.289, filed on Apr. Bioorg. Med. Chem. Letters. 19:4346-4349 (2009). 2, 2012. * cited by examiner (51) Int. Cl. C07D 307/00 (2006.01) Primary Examiner — Nizal Chandrakumar CO7D 49.3/04 (2006.01) (74) Attorney, Agent, or Firm — Mintz, Levin, Cohn, Ferris, A6 IK 45/06 (2006.01) Glovsky and Popeo, P.C. A6 IK3I/365 (2006.01) A6 IK3I/443 (2006.01) (57) ABSTRACT A6 IK3 L/4525 (2006.01) Provided herein, inter alia, are compositions and methods (52) U.S. Cl. useful for treating hyperproliferative diseases, including can CPC ............ C07D493/04 (2013.01); A61K3I/365 cer and non-malignant hyperproliferative diseases. (2013.01); A61 K3I/443 (2013.01); A61 K 3 1/4525 (2013.01); A61K 45/06 (2013.01) 3 Claims, 16 Drawing Sheets U.S. Patent Feb. 23, 2016 Sheet 1 of 16 US 9.266,901 B2 Fig. 1 10 9 - 8 SS 7 s O 6 cy S2 5 Q 4 i. On 3 - 2 1 O CON E2 Fig. 2 15252 O O 5 O p P3 P1 P3 ADH-CD33- ADH-CD 133 U.S. Patent Feb. 23, 2016 Sheet 2 of 16 US 9.266,901 B2 Fig. 3 100 5O O 10 20 50 PTL (micromolar) Fig. 4 1 OO 90 80 70 60 50 40 30 2O 10 Bulk CSC U.S. Patent Feb. 23, 2016 Sheet 3 of 16 US 9.266,901 B2 2 1 2 3 4. 5 6 8 7 8 .x-pass to9 --3028 11 xercissist:12 8 8 t U.S. Patent Feb. 23, 2016 Sheet 4 of 16 US 9.266,901 B2 Fig. 5 (cont'd) 30 2 3 100 4 : 5 6 : 8. 7 8 9 s O .xx. 33.303 10 38.338 Mira &issatist:12 U.S. Patent Feb. 23, 2016 Sheet 5 of 16 US 9.266,901 B2 Fig. 5 (cont'd) 2: WM wim 2:32 win 3282 3 8 . aw 203 4. x-E-- 3:3: 5 0. 53.98 6 88 ww.338 7 wi:2 8 w28 9 exei E2310 W. 2311 wratisatist: 2 U.S. Patent Feb. 23, 2016 Sheet 6 of 16 US 9.266,901 B2 Fig. 5 (cont'd) 4. 2 O O O LM O. M. LV 10 M OOM isa. 120 ar 8x. .3 : 48 5 100 as: rx -x-Ja26; ; --- 28 SSs - & ::...&.823 Yr 8-2 ------------------kissata ; ise 108 80 88 2 66 a. - 4 S. a 20 26 8 23 : & O2 2 --&-23 recisolatin U.S. Patent Feb. 23, 2016 Sheet 7 of 16 US 9.266,901 B2 28 S 28 202 23 Cispati + 5 uy Cispiatin 81 22 283 Cisplatin + S v Cispiatin 8 Fig. 7 p-NFkBp65 NFkBp65 U.S. Patent Feb. 23, 2016 Sheet 10 of 16 US 9.266,901 B2 Fig. F. :rest Cr-fig2. feath:8::ciay U.S. Patent Feb. 23, 2016 Sheet 11 of 16 US 9.266,901 B2 Fig. 12 inflammatory Cytokines, Growth Factors, CD23,CE)3CD28, LPS, Fas, etc. IL-1R K.E. S. &3;&de Cascais Caspase poly. Apoptosis ibiguitination eer Proteasone degradation Activated NFkB N Parthenoides inhibit plays a Central role Se:S36 NFkB activation and in regulating Active NF-kB binding to DNA malignant Se:2's progression Serai Cytokines, Chesnakiries, Nucleus raisciption Transcriptior Factors. T Adaesion votecuies KB site Actite raise Pigtairs, ix3-c. U.S. Patent Feb. 23, 2016 Sheet 12 of 16 US 9.266,901 B2 Fig. 12 cont'd t sixx c Sass :: Ssss 8:::::::: Fig. 3 6 & 3. S. : p-NFkBp65 U.S. Patent Feb. 23, 2016 Sheet 13 of 16 US 9.266,901 B2 Fig. 14 8 34 CO, TMR HER NFkB Reporter Fig. 15 4 1. 1. Drug Dose (micromolar) U.S. Patent Feb. 23, 2016 Sheet 14 of 16 US 9.266,901 B2 Fig. 6 Xs. 1 a ;3 {".g. 888 fi: 8; 8.3: U.S. Patent Feb. 23, 2016 Sheet 15 of 16 US 9.266,901 B2 Fig. 17 f 5 3. CO TR I-IFkB Reporter Fig. 18 ; 8: 88. k . - A - 203+TZ : -- TZ--2O3 Vh 8: 0.1 1.0 10 50 Drug Dose (micromolar) U.S. Patent Feb. 23, 2016 Sheet 16 of 16 US 9.266,901 B2 Fig. 19 -------------------------------------------------- US 9,266,901 B2 1. 2 COMPOSITIONS AND METHODS FOR either TSC1 or TSC2 and in hamartomas of TSC patients. TREATING CANCER TSC can occur in association with pulmonary lymphangiolei omyomatosis (LAM), a progressive and often fatal interstitial CROSS-REFERENCES TO RELATED lung disease that occurs largely in women and is character APPLICATIONS ized by proliferation of abnormal smooth muscle cells. TSC2 null Smooth muscle cells in angiomyolipomas (AML) are This application is a continuation application of interna very similar to those of pulmonary LAM, and data Suggest tional PCT application No. PCT/US2013/035.010, filed Apr. LAM may be the result of benign cell metastases. Rapamycin 2, 2013, which claims the benefit of U.S. Provisional Patent and related drugs (everolimus) which bind and inhibit Application No. 61/619.289, filed Apr. 2, 2012, which are 10 mTORC1 have clinical activity for therapy of TSC, including incorporated herein by reference in their entirety and for all renal AML and pulmonary LAM (72). However, rapamycin purposes. does not elicit complete TSC regression in most cases, and STATEMENT AS TO RIGHTS TO INVENTIONS termination of therapy oft leads to lesion re-growth. New MADE UNDER FEDERALLY SPONSORED 15 therapeutic approaches to control the growth of TSC-related RESEARCH AND DEVELOPMENT proliferative diseases are urgently needed. The poor prognosis of advanced non-Small cell lung cancer This invention was made with Government support under (NSCLC) is due, in part, to emergence of tumor resistance to DAMD17-03-1-0381, awarded by the U.S. Army, Medical chemotherapy (1). Recent data indicate that human tumors Research and Materiel Command. The Government has cer contain a small subset of cancer stem cells (CSC) responsible tain rights in the invention. for drug resistance and tumor maintenance (2-5). If Such minute subsets of CSC drive tumor formation and drug resis BACKGROUND tance, therapies targeting the bulk tumor mass but not CSC will fail. Since it is hypothesized that CSC are responsible for Lung Cancer is the leading cause of cancer death in women 25 tumor regeneration after chemo-therapy (6), we performed and men in the U.S. It is estimated that there will be more than preliminary studies to determine if drug treatment could 230,000 patients diagnosed with lung cancer this year, with enrich for CSCs. Treatment of human lung tumor NSCLC cell more than 160,000 deaths, and non-small cell lung cancer lines (A549, H23) with increasing doses of cisplatin resulted (NSCLC) will account for more than three quarters of these in selection of drug-resistant cells (DRC)(6). Using Fluores cases (1). Survival rates of NSCLC, the predominant type of 30 cence Activated Cell Sorting (FACS), DRC were selected for lung cancer are unacceptably low, and new approaches to expression of cell surface CD133+ and cytosolic ALDH1 by treat and prevent this disease are urgently needed. Feverfew Aldefluor assay (7.8), yielding cell subsets amounting to extracts and parthenolide show anticancer activity in NSCLC 2%-5% of bulk tumor cell populations of H23 and A549, in vitro, while parthenolides modified to enhance solubility respectively. Furthermore, CSC-like cells grew as tumor also show significant anticancer activity in vivo in NSCLC 35 spheres, maintained self-renewal capacity and differentiated, models. This anticancer effect may be associated with the with differentiated progenitors losing CD133 expression and ability of these substances to inhibit the nuclear transcription acquiring drug sensitivity.
Load more

Recommended publications
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Targeting the Deubiquitinase STAMBP Inhibits NALP7 Inflammasome
    ARTICLE Received 19 Jul 2016 | Accepted 8 Mar 2017 | Published 11 May 2017 DOI: 10.1038/ncomms15203 OPEN Targeting the deubiquitinase STAMBP inhibits NALP7 inflammasome activity Joseph S. Bednash1, Nathaniel Weathington1, James Londino1, Mauricio Rojas1, Dexter L. Gulick1, Robert Fort1, SeungHye Han1, Alison C. McKelvey1, Bill B. Chen1 & Rama K. Mallampalli1,2,3 Inflammasomes regulate innate immune responses by facilitating maturation of inflammatory cytokines, interleukin (IL)-1b and IL-18. NACHT, LRR and PYD domains-containing protein 7 (NALP7) is one inflammasome constituent, but little is known about its cellular handling. Here we show a mechanism for NALP7 protein stabilization and activation of the inflammasome by Toll-like receptor (TLR) agonism with bacterial lipopolysaccharide (LPS) and the synthetic acylated lipopeptide Pam3CSK4. NALP7 is constitutively ubiquitinated and recruited to the endolysosome for degradation. With TLR ligation, the deubiquitinase enzyme, STAM-binding protein (STAMBP) impedes NALP7 trafficking to lysosomes to increase NALP7 abundance. STAMBP deubiquitinates NALP7 and STAMBP knockdown abrogates LPS or Pam3CSK4-induced increases in NALP7 protein. A small-molecule inhibitor of STAMBP deubiquitinase activity, BC-1471, decreases NALP7 protein levels and suppresses IL-1b release after TLR agonism. These findings describe a unique pathway of inflammasome regulation with the identification of STAMBP as a potential therapeutic target to reduce pro-inflammatory stress. 1 Department of Medicine, Acute Lung Injury Center of Excellence, University of Pittsburgh, UPMC Montefiore, NW 628, Pittsburgh, Pennsylvania 15213, USA. 2 Departments of Cell Biology and Physiology and Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA. 3 Medical Specialty Service Line, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania 15240, USA.
    [Show full text]
  • Multiple Myeloma Inhibitory Activity of Plant Natural Products
    cancers Review Multiple Myeloma Inhibitory Activity of Plant Natural Products Karin Jöhrer 1 and Serhat Sezai Ҫiҫek 2,* 1 Tyrolean Cancer Research Institute, Innrain 66, 6020 Innsbruck, Austria; karin.joehrer@tkfi.at 2 Department of Pharmaceutical Biology, Kiel University, Gutenbergstraße 76, 24118 Kiel, Germany * Correspondence: [email protected] Simple Summary: Multiple myeloma is the second most common hematological cancer and is still incurable. Although enhanced understanding of the disease background and the development of novel therapeutics during the last decade resulted in a significant increase of overall survival time, almost all patients relapse and finally succumb to their disease. Therefore, novel medications are urgently needed. Nature-derived compounds still account for the majority of new therapeutics and especially for the treatment of cancer often serve as lead compounds in drug development. The present review summarizes the data on plant natural products with in vitro and in vivo activity against multiple myeloma until the end of 2020, focusing on their structure–activity relationship as well as the investigated pathways and involved molecules. Abstract: A literature search on plant natural products with antimyeloma activity until the end of 2020 resulted in 92 compounds with effects on at least one human myeloma cell line. Compounds were divided in different compound classes and both their structure–activity-relationships as well as eventual correlations with the pathways described for Multiple Myeloma were discussed. Each of the major compound classes in this review (alkaloids, phenolics, terpenes) revealed interesting candidates, such as dioncophyllines, a group of naphtylisoquinoline alkaloids, which showed pronounced Citation: Jöhrer, K.; Ҫiҫek, S.S.
    [Show full text]
  • A 0.70% E 0.80% Is 0.90%
    US 20080317666A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317666 A1 Fattal et al. (43) Pub. Date: Dec. 25, 2008 (54) COLONIC DELIVERY OF ACTIVE AGENTS Publication Classification (51) Int. Cl. (76) Inventors: Elias Fattal, Paris (FR); Antoine A6IR 9/00 (2006.01) Andremont, Malakoff (FR); A61R 49/00 (2006.01) Patrick Couvreur, A6II 5L/12 (2006.01) Villebon-sur-Yvette (FR); Sandrine A6IPI/00 (2006.01) Bourgeois, Lyon (FR) (52) U.S. Cl. .......................... 424/1.11; 424/423; 424/9.1 (57) ABSTRACT Correspondence Address: Drug delivery devices that are orally administered, and that David S. Bradlin release active ingredients in the colon, are disclosed. In one Womble Carlyle Sandridge & Rice embodiment, the active ingredients are those that inactivate P.O.BOX 7037 antibiotics, such as macrollides, quinolones and beta-lactam Atlanta, GA 30359-0037 (US) containing antibiotics. One example of a Suitable active agent is an enzyme Such as beta-lactamases. In another embodi ment, the active agents are those that specifically treat colonic (21) Appl. No.: 11/628,832 disorders, such as Chrohn's Disease, irritable bowel syn drome, ulcerative colitis, colorectal cancer or constipation. (22) PCT Filed: Feb. 9, 2006 The drug delivery devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethylene imine. The high crosslink density of the polyethyleneimine is (86). PCT No.: PCT/GBO6/OO448 believed to stabilize the pectin beads for a sufficient amount of time such that a Substantial amount of the active ingredi S371 (c)(1), ents can be administered directly to the colon.
    [Show full text]
  • Late-Breaking Abstracts
    Late‐Breaking Abstracts ___________________________________________________________________ Late‐Breaking Abstracts Table of Contents Pg 2 Adaptive and Auto‐Immunity Abstracts LB708 – LB712 Pg 4 Carcinogenesis and Cancer Genetics Abstracts LB713 – LB715 Pg 6 Cell‐Cell Interactions in the Skin Abstracts LB716 – LB722 Pg 9 Epidermal Structure and Barrier Function Abstracts LB723 – LB730 Pg 13 Genetic Disease, Gene Regulation, and Gene Therapy Abstracts LB731 – LB735 Pg 15 Innate Immunity, Microbiology, and Microbiome Abstracts LB736 – LB740 Pg 18 Patient Population Research Abstracts LB741 – LB771 Pg 33 Patient‐Targeted Research Abstracts LB772 – LB782 Pg 39 Pharmacology and Drug Development Abstracts LB783 – LB795 Pg 45 Photobiology Abstracts LB796 – LB802 Pg 48 Pigmentation and Melanoma Abstracts LB803 – LB804 Pg 49 Skin of Color Abstracts LB805 ‐ LB806 Pg 50 Skin, Appendages, and Stem Cell Biology Abstracts LB807 Pg 51 Tissue Regeneration and Wound Healing Abstracts LB808 – LB811 Pg 53 Translational Studies Abstracts LB812 – LB823 Pg 59 Author Index Pg 65 Keyword Index 1 Adaptive and Auto-Immunity LB708 ILC1-like innate lymphocytes in human autoimmunity: Lessons from Alopecia Areata R. Laufer Britva1, A. Keren1, M. Bertolini2, R. Paus3, 4, A. Gilhar1 1Technion Israel Institute of Technology, Haifa, Haifa, Israel, 2Monasterium, Münster, Germany, 3Department of Dermatology & Cutaneous Surgery, University of Miami School of Medicine, Miami, Florida, United States, 4Dermatology Research Centre, University of Manchester, Manchester, Germany Innate lymphoid cells type 1 (ILC1) express NKG2D and produce large amounts of IFN-γ, i.e. two key elements in the pathogenesis of alopecia areata (AA). In this study, we aimed to explore a possible involvement of ILC1-like cells in human AA by using ex-vivo and in-vivo models for human AA.
    [Show full text]
  • {Replace with the Title of Your Dissertation}
    SYNTHESIS AND EVALUATION OF PARTHENOLIDE ANALOGUES: CHEMICAL PROBES AND THERAPEUTIC AGENTS A Thesis SUBMITTED TO THE FACULTY OF UNIVERSITY OF MINNESOTA BY Dan Wang IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE Advisor: Dr. Daniel A. Harki MARCH 2013 © Dan Wang 2013 Acknowledgements I would like to begin by thanking my advisor, Dr. Dan Harki for his mentorship and support over these years. Your wisdom, knowledge and enthusiasm for science were a guiding light throughout my graduate school career. I wouldn’t be where I am without your vision, encouragement and advise. Additional thanks goes to Professor Rick Wagner, Professor Chengguo Xing and Professor Mark Distefano for serving on my dissertation committee, and for the helpful critiques and suggestions provided throughout my graduate career. Then, I would like to extend my sincere thanks to every past and present member of Harki group. Thank you all for the scientific help you have provided me all these years as well as being a constant source of support. In particular, Dr. Fred Meece for guiding me into the “parthenolide field” and Joe Hexum and Tim Andrew for providing some of the biological data in chapter 2. I would also like to thank and recognize my collaborators for all their assistance with regards to my projects. In particular, I would like to thank Professor David Largaespada, Sue Rathe and Zohar Sachs for their help and valuable discussion in primary AML cells; Professor John Ohlfest and Chani Becker for performing the brain tumor animal studies; Dr. Victor G. Young, Jr.
    [Show full text]
  • Localized Rnas Involves Silencing and Clustering After Transport Konstadinos Moissoglu1†, Kyota Yasuda1,2,3†, Tianhong Wang1†, George Chrisafis1, Stavroula Mili1*
    RESEARCH ARTICLE Translational regulation of protrusion- localized RNAs involves silencing and clustering after transport Konstadinos Moissoglu1†, Kyota Yasuda1,2,3†, Tianhong Wang1†, George Chrisafis1, Stavroula Mili1* 1Laboratory of Cellular and Molecular Biology,Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, United States; 2Program of Mathematical and Life Sciences, Graduate School of Integrated Science for Life, Hiroshima University, Higashi-Hiroshima, Japan; 3Laboratory for Comprehensive Bioimaging, RIKEN Center for Biosystems Dynamics Research, Suita, Japan Abstract Localization of RNAs to various subcellular destinations is a widely used mechanism that regulates a large proportion of transcripts in polarized cells. In many cases, such localized transcripts mediate spatial control of gene expression by being translationally silent while in transit and locally activated at their destination. Here, we investigate the translation of RNAs localized at dynamic cellular protrusions of human and mouse, migrating, mesenchymal cells. In contrast to the model described above, we find that protrusion-localized RNAs are not locally activated solely at protrusions, but can be translated with similar efficiency in both internal and peripheral locations. Interestingly, protrusion-localized RNAs are translated at extending protrusions, they become translationally silenced in retracting protrusions and this silencing is accompanied by coalescence of single RNAs into larger heterogeneous RNA clusters. This work describes a distinct mode of *For correspondence: translational regulation of localized RNAs, which we propose is used to regulate protein activities [email protected] during dynamic cellular responses. DOI: https://doi.org/10.7554/eLife.44752.001 †These authors contributed equally to this work Competing interests: The authors declare that no Introduction competing interests exist.
    [Show full text]
  • Curriculum Vitae
    Curriculum Vitae Dr. Shyam S. Sharma Professor Department of Pharmacology and Toxicology National Institute of Pharmaceutical Education and Research (NIPER) Sector 67, S.A.S. Nagar (Mohali) – 160062, Punjab, INDIA Email: [email protected]; [email protected] Dr Shyam S Sharma is a Professor in the Department of Pharmacology and Toxicology at the National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India since 2009. Before joining NIPER Mohali, he worked as postdoctoral fellow at the University of Illinois at Chicago, USA and did his PhD (Pharmacology) at the All India Institute of Medical Sciences (AIIMS), New Delhi. Dr Sharma has published more than 150 peer reviewed research papers/patents/book chapters with more than 5000 citations, h-index 39, and i10-index 97 https://scholar.google.co.in/citations?user=yieVPfgAAAAJ&hl=en. His research interests includes understanding the potential role of pharmacological agents in CNS disorders (cerebral ischemia, Parkinson’s disease, Alzheimer’s disease), diabetic complications (neuropathic pain, cognitive impairment, cardiomyopathy), cardiovascular diseases, and safety pharmacology. He has more than 20 years of teaching (master’s and doctorate students) and research experience. Dr Sharma has guided more than 100 master’s and doctorate students. He has delivered more than 100 invited talks at national & international levels. He has completed more than 20 extramural and industry funded projects. He is recipient of Organisation for Pharmaceutical Producers of India (OPPI) Scientist Award, Shakuntala Amir Chand Prize and Dr D N Prasad Memorial Oration Award of Indian Council of Medical Research, CDRI Oration award, PP Suryakumari Prize and Prof.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0155575 A1 Bai Et Al
    US 2014O155575A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0155575 A1 Bai et al. (43) Pub. Date: Jun. 5, 2014 (54) PROCESS OF PREPARING GUANYLATE (86). PCT No.: PCT/US 12/27287 CYCLASE CAGONSTS S371 (c)(1), (2), (4) Date: Feb. 11, 2014 (75) Inventors: Juncai Bai, North Augusta, SC (US); Related U.S. Application Data Ruoping Zhang, North Augusta, SC (US); Jun Jian, Shanghai (CN); Junfeng (60) Provisional application No. 61/447,891, filed on Mar. Zhou, Shanghai (CN); Qiao Zhao, 1, 2011. Shanghai (CN); Guoquing Zhang, Publication Classification Shanghai (CN); Kunwar Shailubhai, Audubon, PA (US); Stephen Comiskey, (51) Int. Cl. Doylestown, PA (US); Rong Feng, C07K 7/64 (2006.01) Langhorne, PA (US) C07K 7/08 (2006.01) (52) U.S. Cl. CPC. C07K 7/64 (2013.01); C07K 7/08 (2013.01) (73) Assignee: SYNERGY PHARMACEUTICALS USPC ........................................... 530/321:530/326 INC., New York, NY (US) (57) ABSTRACT (21) Appl. No.: 14/001,638 The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group (22) PCT Fled: Mar. 1, 2012 consisting of SEQID NOs: 1-249 described herein. Patent Application Publication Jun. 5, 2014 Sheet 1 of 3 US 2014/O155575A1 16d -aw C.CD N.5 CN OCD SRCD SNCN ( . CN C S O d. C-S V 3c : SS-$C O. htCD as hCD S.> a. N N N. NN C N. NN v N s i s Š : CN CN w- w (WM) peulee 9. Patent Application Publication Jun. 5, 2014 Sheet 2 of 3 US 2014/O155575A1 FIG.
    [Show full text]
  • Activation of a Nuclear Factor KB/Interleukin-1 Positive Feedback Loop by Amphiregulin in Human Breast Cancer Cells
    Published OnlineFirst August 1, 2007; DOI: 10.1158/1541-7786.MCR-06-0427 Published Online First on August 1, 2007 Activation of a Nuclear Factor KB/Interleukin-1 Positive Feedback Loop by Amphiregulin in Human Breast Cancer Cells Katie L. Streicher,1 Nicole E. Willmarth,1,4 Jose Garcia,5 Julie L. Boerner,1,2 T. Gregory Dewey,5 and Stephen P. Ethier1,3 1Breast Cancer Program, Karmanos Cancer Institute and Departments of 2Pharmacology and Department of 3Pathology, Wayne State University School of Medicine, Detroit, Michigan; 4Cellular and Molecular Biology Graduate Program, University of Michigan, Ann Arbor, Michigan; and 5Keck Graduate Institute of Applied Life Sciences, Claremont, California Abstract mammary epithelial cells growing in the presence of We have recently shown that an amphiregulin-mediated amphiregulin, EGFR signaling is integrated with NF-KB autocrine loop is responsible for growth factor– activation and IL-1 synthesis, which cooperate to independent proliferation, motility, and invasive capacity regulate the growth and invasive capacity of the cells. of some aggressive breast cancer cells, such as the (Mol Cancer Res 2007;5(8):OF1–15) SUM149 breast cancer cell line. In the present study, we investigated the mechanisms by which amphiregulin activation of the epidermal growth factor receptor Introduction (EGFR) regulates these altered phenotypes. The epidermal growth factor (EGF) receptor (EGFR), or Bioinformatic analysis of gene expression networks erbB1, is a transmembrane protein (1) possessing intrinsic regulated by amphiregulin implicated interleukin-1A tyrosine kinase activity.There are several EGF family ligands (IL-1A) and IL-1B as key mediators of amphiregulin’s that can bind and activate EGFR, including epidermal growth biological effects.
    [Show full text]
  • Consensus Molecular Subtype Differences Linking Colon Adenocarcinoma and Obesity Revealed by a Cohort Transcriptomic Analysis
    medRxiv preprint doi: https://doi.org/10.1101/2021.08.31.21262900; this version posted September 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Title: Consensus molecular subtype differences linking colon adenocarcinoma and obesity revealed by a cohort transcriptomic analysis Short Title: Obesity and colon cancer Michael W. Greene1*, Peter T. Abraham2, Peyton C. Kuhlers1,3, Elizabeth A. Lipke2, Martin J. Heslin4, Stanley T. Wijaya1 and Ifeoluwa Odeniyi1 1Department of Nutrition, Dietetics, and Hospitality Management, Auburn University, Auburn, AL 36849, USA 2Department of Chemical Engineering, Auburn University, Auburn, AL 36849, USA 3Department of Biostatistics, University of North Carolina at Chapel Hill, NC 27599, USA 4Mitchell Cancer Institute, The University of South Alabama, Mobile, AL 36604, USA *Corresponding author: Michael W. Greene [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2021.08.31.21262900; this version posted September 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Abstract Background Colorectal cancer (CRC) is the third-leading cause of cancer-related deaths in the United States and worldwide.
    [Show full text]
  • Lessons Learned
    Prevention and Reversal of Chronic Disease Copyright © 2019 RN Kostoff PREVENTION AND REVERSAL OF CHRONIC DISEASE: LESSONS LEARNED By Ronald N. Kostoff, Ph.D., School of Public Policy, Georgia Institute of Technology 13500 Tallyrand Way, Gainesville, VA, 20155 [email protected] KEYWORDS Chronic disease prevention; chronic disease reversal; chronic kidney disease; Alzheimer’s Disease; peripheral neuropathy; peripheral arterial disease; contributing factors; treatments; biomarkers; literature-based discovery; text mining ABSTRACT For a decade, our research group has been developing protocols to prevent and reverse chronic diseases. The present monograph outlines the lessons we have learned from both conducting the studies and identifying common patterns in the results. The main product of our studies is a five-step treatment protocol to reverse any chronic disease, based on the following systemic medical principle: at the present time, removal of cause is a necessary, but not necessarily sufficient, condition for restorative treatment to be effective. Implementation of the five-step treatment protocol is as follows: FIVE-STEP TREATMENT PROTOCOL TO REVERSE ANY CHRONIC DISEASE Step 1: Obtain a detailed medical and habit/exposure history from the patient. Step 2: Administer written and clinical performance and behavioral tests to assess the severity of symptoms and performance measures. Step 3: Administer laboratory tests (blood, urine, imaging, etc) Step 4: Eliminate ongoing contributing factors to the chronic disease Step 5: Implement treatments for the chronic disease This individually-tailored chronic disease treatment protocol can be implemented with the data available in the biomedical literature now. It is general and applicable to any chronic disease that has an associated substantial research literature (with the possible exceptions of individuals with strong genetic predispositions to the disease in question or who have suffered irreversible damage from the disease).
    [Show full text]